FDA approves Eli Lilly's weight-loss pill orforglipron under expedited review process
The FDA approved Eli Lilly's new daily weight-loss pill orforglipron (branded as Foundayo) under an expedited 50-day review process. In clinical trials, patients taking the highest dose lost an average of 11.2% of their body weight over 16 months. The pill will cost $25-349 per month depending on insurance and dosage, with shipping beginning Monday.
23
Divergence score
5 outlets covered it, splitting into 5 framing camps across 3 bias groups.
5 camps
3 bias groups
The spectrum · how 5 outlets placed this story
LeftCenterRight
CNN
NY Post
PBS NewsHour
Reuters
The Hill
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
The split, in one line
Business outlets frame this as competitive battle with Novo Nordisk, health-focused sources emphasize patient accessibility and convenience benefits, while wire coverage sticks to regulatory details.
How each outlet covered it
Broad agreement on what happened
Outlets across the spectrum land in roughly the same place: the shared language is highlighted.
THE LEFT
“Another GLP-1 weight loss pill gets FDA approval, and it has fewer restrictions on how it's used”CNN CNN LEFT
23LOW DIVERGENCE
THE RIGHT
“What to know about new 'triple-G' drug that's helped patients lose a quarter of their body weight”NYP NY Post RIGHT
DOWN THE MIDDLE
“Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk” · PBS NewsHour, Reuters, The Hill
+Hide the full sourcingSee how all 5 outlets put it
Tracked claims from across the political spectrum
Fact ledger
Corroborated
Disputed